IntraBio has secured a second approval for its therapy Aqneursa, this time as the first treatment in the world for a rare ataxia. The expansion adds to the drugmaker's momentum in the rare neurological disease space, where it has now logged multiple regulatory wins.
The new indication makes Aqneursa the first and only therapy available for this specific ataxia, a group of disorders marked by progressive loss of motor coordination. The approval builds on the drug's existing use, though the source does not specify the exact ataxia subtype or the mechanism of action.
With this decision, IntraBio continues to establish itself as a key player in rare neurological conditions. The company's pipeline and regulatory track record suggest further expansions may be on the horizon, though no additional details were provided in the announcement.